

PTO/SB/26 (09-04) Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING **REJECTION OVER A "PRIOR" PATENT**

Docket Number (Optional)

56959C1

In re Application of: Michael STROBEL

Application No.: 10/806,683

Filed: June 6, 2003

For: Application of Water and Organic Solvent Soluble Ivermectin for Topical and Oral Use

The owner*, Pharmaceutical Solutions, Inc., of 100 percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application which would extend beyond the expiration date of the full statutory term prior patent No. 6,627,613 as the term of said prior patent is defined in 35 U.S.C. 154 and 173, and as the term of said prior patent is presently shortened by any terminal disclaimer. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the prior patent are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, the owner does not disclaim the terminal part of the term of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 and 173 of the prior patent

application that modified of the complication and t		•
patent, "as the term of said prior patent is presently shortened by any termin	nal disclaimer," in the ev	ent that said prior patent
ater:		
expires for failure to pay a maintenance fee;		
is held unenforceable;		
is found invalid by a court of competent jurisdiction; is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.3	191•	•
has all claims canceled by a reexamination certificate;	98/28/2006 MAKMED1	00000022 10806683
is reissued, or		[38,00 07
is in any manner terminated prior to the expiration of its full statutory term a	ıs pr êserik) elf ortened t	y any terminal disclaimer.
Check either box 1 or 2 below, if appropriate.		
1. For submissions on behalf of an organization (e.g., corporation, partn	ership, university, gove	nment agency,
etc.), the undersigned is empowered to act on behalf of the business/o	rganization.	
I hereby declare that all statements made herein of my own knowled		
nformation and belief are believed to be true; and further that these statemer		
alse statements and the like so made are punishable by fine or imprisonmen	t, or both, under Section	n 1001 of Title 18 of the
United States Code and that such willful false statements may jeopardize the	validity of the application	on or any patent issued
hereon.		
2. The undersigned is an attorney or agent of record. Reg. No. 33,771		
Signatule		23, 2006
	D	ate
John W. Ryan		· · · - · · - · · · · · · · · · · · · ·
Typed or printed nam	⁶ (202) 624-	2740
	Telephon	e Number
_		
Terminal disclaimer fee under 37 CFR 1.20(d) is included.		
WARNING: Information on this form may become public. Cr	edit card information s	hould not
be included on this form. Provide credit card information a	and authorization on Pl	O-2038.
*Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed	by the assignee (owner).	
Form PTO/SB/96 may be used for making this statement. See MPEP § 324.	,	

This collection of information is required by 37 CFR 1.321. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.